OnKure Therapeutics, Inc. (OKUR) Key Metrics
OKUR valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $85.0M
- Enterprise value
- −$54.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.7
- EV / EBITDA
- 0.0
- Dividend yield
- —
- Beta
- 0.75
OKUR key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsOKUR valuation Price multiples at each fiscal year-end price.
OKUR returns How much profit the business earns on the capital it uses.
OKUR per-share figures Results divided by the shares outstanding at year-end.
OKUR financial health Debt, liquidity and how easily interest is covered.
OKUR efficiency & capital use Working capital cycle and where the cash goes.
OKUR valuation history
OKUR returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
OKUR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
OKUR price vs earnings per share
OKUR key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $39.2M | $114.7M | $213.4M | $310.8M | — | — |
| Enterprise value | −$19.3M | $5.0M | $184.2M | $299.9M | — | — |
| Price / book | 0.7 | 1.1 | — | — | — | — |
| Earnings yield | −151.8% | −45.9% | −16.5% | −9.5% | — | — |
| Free cash flow yield | −132.3% | −44.6% | −16.3% | −9.0% | — | — |
| Share price at fiscal year-end | $2.90 | $8.60 | $16.00 | $23.30 | $85.50 | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Earnings per share | −$4.40 | −$3.95 | −$2.65 | −$2.21 | — | — |
| Operating cash flow per share | −$3.83 | −$3.83 | −$2.59 | −$2.02 | — | — |
| Free cash flow per share | −$3.84 | −$3.84 | −$2.61 | −$2.11 | — | — |
| Cash per share | $4.37 | $8.30 | $2.24 | $0.87 | — | — |
| Book value per share | $4.16 | $7.78 | −$7.63 | −$4.08 | — | — |
| Tangible book value per share | $4.16 | $7.78 | −$7.63 | −$4.08 | — | — |
| Capex per share | $0.00 | $0.00 | $0.02 | $0.09 | — | — |
| Debt per share | $0.04 | $0.08 | $0.05 | $0.05 | — | — |
| Shares outstanding | 13.5M | 13.3M | 13.3M | 13.3M | — | — |
| Change in shares outstanding | +1.3% | 0.0% | 0.0% | — | — | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −74.4% | — | — | — | −75.7% | — |
| Return on assets (ROA) | −67.2% | −69.9% | −136.5% | −34.7% | −38.0% | −35.2% |
| Return on tangible assets | −95.8% | −45.8% | −98.8% | −184.5% | −25.8% | −35.2% |
| Financial health | ||||||
| Total debt | $549,000 | $1.1M | $674,000 | $637,000 | — | $92.7M |
| Cash & short-term investments | $59.0M | $110.8M | $29.9M | $11.5M | $147.7M | $53.6M |
| Net debt | −$58.5M | −$109.7M | −$29.2M | −$10.9M | −$147.7M | $39.1M |
| Debt / equity | 0.01 | 0.01 | — | — | — | — |
| Debt / assets | 0.01 | 0.01 | 0.02 | 0.04 | — | 1.68 |
| Current ratio | 10.28 | 10.73 | 4.64 | 2.46 | 24.79 | 12.01 |
| Quick ratio | 10.28 | 10.73 | 4.64 | 2.46 | 24.79 | 12.01 |
| Interest coverage | — | -181.3 | — | — | — | — |
| Working capital | $54.9M | $102.5M | $26.5M | $8.1M | $147.5M | $50.4M |
| Invested capital | −$2.3M | −$5.8M | −$131.0M | −$65.3M | −$459,000 | −$3.0M |
| Tangible asset value | $56.2M | $103.8M | −$101.8M | −$54.4M | $147.2M | −$42.1M |
| Net current asset value | $54.9M | $101.9M | −$103.8M | −$56.8M | $146.9M | −$42.3M |
| Graham net-net per share | $3.93 | $7.47 | −$8.07 | −$4.41 | — | — |
| Capital allocation | ||||||
| Capex / depreciation | 0.06 | 0.08 | 0.44 | 2.93 | 3.96 | 0.65 |
| Efficiency | ||||||
| Days payables outstanding | 967.7 | 1,760.2 | 1,934.8 | 1,738.8 | — | — |
| Payables turnover | 0.38 | 0.21 | 0.19 | 0.21 | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $2.2M | $3.2M | $3.0M | $2.5M | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from OKUR's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
OKUR valuation and financial ratios
OnKure Therapeutics earned a return on equity of −74.4% in fiscal 2025. It ended the year with $0.5 million of debt and $59.0 million in cash and short-term investments, a net cash position of $58.5 million.
See the OKUR income statement, the OKUR chart for price history, or the OKUR stock overview for the latest quote and news.
OKUR key metrics FAQ
What is OnKure Therapeutics's return on equity?
OnKure Therapeutics's return on equity (ROE) was −74.4% in fiscal 2025: net income of -$59.5 million on average shareholders' equity of $80.0 million.
How much debt does OnKure Therapeutics have?
OnKure Therapeutics had total debt of $0.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is OnKure Therapeutics's free cash flow yield?
OnKure Therapeutics generated -$51.9 million of free cash flow in fiscal 2025, a free cash flow yield of −132.3% on its market value at year-end ($39.2 million).
What is OnKure Therapeutics's current ratio?
OnKure Therapeutics's current ratio was 10.28 at the end of fiscal 2025: current assets were 10.28 times current liabilities.